Drug Profile
AZD 0466
Alternative Names: AZD-0466Latest Information Update: 30 Jan 2024
Price :
$50
*
At a glance
- Originator AstraZeneca
- Developer AstraZeneca; Starpharma
- Class Antineoplastics; Dendrimers; Drug conjugates; Small molecules
- Mechanism of Action Bcl-X protein inhibitors; Proto-oncogene protein c-bcl-2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Haematological malignancies; Lymphoma; Mantle-cell lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma; Small cell lung cancer; Solid tumours
Most Recent Events
- 09 Dec 2023 Pharmacodynamics data from a preclinical trial in Chronic Lymphocytic Leukemia presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-2023)
- 17 Aug 2023 AstraZeneca terminates a phase-I/II trial in Non-Hodgkin's lymphoma (In adults, In the elderly, Monotherapy, Combination therapy, Late-stage disease, Second-line therapy or greater) in Australia, Canada, France, Germany, Italy, Portugal, South Korea, Spain and USA due to safety reasons (IV) (NCT05205161) (EudraCT2021-003410-39)
- 08 Aug 2023 AstraZeneca terminates a phase I/II trial in Haematological malignancies (In the elderly, In adults, Late-stage disease) in USA, Australia, Italy, Germany, France, South Korea (IV) based on benefit-risk profile assessment (NCT04865419) (EudraCT2020-005106-25)